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IMPORTANCE The literature onMerkel cell carcinoma (MCC) of the eyelid remains scarce, and
there has yet to be a study using themost up-to-date TNM staging system for this rare but
aggressive tumor.
OBJECTIVE To analyze the TNM stage, management, and outcomes of patients with MCC of
the eyelid.
DESIGN, SETTING, AND PARTICIPANTS Retrospective case series of 21 patients from 5 tertiary
referral centers in the United Kingdom and Australia with primary MCC of the eyelid
presenting at a median age of 77 years, with median follow-up of 54months. Tumors were
staged according to the American Joint Committee on Cancer, 7th edition, TNM criteria for
eyelid carcinoma andMCC.
MAIN OUTCOMES ANDMEASURES TNM stage, treatmentmodalities, and clinical outcome.
RESULTS The eyelid carcinoma TNM stages were T2aN0M0 for 5 patients, T2bN0M0 for 7
patients, T3aN0M0 for 4 patients, T3bN0M0 for 3 patients, T2bN1M0 for 1 patient, and
T3aN1M0 for 1 patient. TheMCC TNM stages were T1N0M0 for 12 patients, T2N0M0 for 7
patients, T1N1M0 for 1 patient, and T2N1M0 for 1 patient. One patient had a sentinel lymph
node biopsy, and 8 patients underwent head/neck imaging. Eighteen patients underwent a
wide local excision, 12 with a paraffin section and 6with a frozen section. Two patients
underwent Mohs surgery, 1 of whom required an orbital exenteration. Twelve patients (57%)
received adjuvant radiotherapy, and 2 patients received chemotherapy. The local recurrence
rate was 10%, the regional nodal recurrence rate was 10%, and the distant metastatic
recurrence rate was 19%. The lowest T category tumor metastasizing to both regional nodes
and distant locations was a T2a (eyelid TNM)/T1 (Merkel TNM) tumor measuring 8mm. Two
patients with T3a (eyelid TNM)/T2 (Merkel TNM) tumors died of metastatic MCC.
CONCLUSIONS AND RELEVANCE Themajority of patients withMCC of the eyelid present with
localized eyelid disease of T category T2 (eyelid TNM)/T1 (Merkel TNM). A wide local excision
with margin control remains themainstay of treatment, whereas the use of radiotherapy is
institution specific. Tumors with a low T category are associated with regional nodal and
distant metastatic disease. It may therefore be reasonable to consider a sentinel lymph node
biopsy or strict regional lymph node surveillance for all MCCs of the eyelid, regardless of T
category or size.
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M erkel cell carcinoma (MCC) is an aggressive skin tu-mor thatwas firstdescribed in1972andthathassincebeen increasing in incidence.1,2 Established risk fac-
tors for MCC include immunosuppression and extensive sun
exposure,andMerkelcellpolyomavirushasrecentlybeen iden-
tified in 80% of MCCs.3-5 The estimated mortality rate for all
patients with MCC is 25% to 35%.6 Involvement of the eyelid
occurs in 10% of cases, with an annual incidence of approxi-
mately 0.23 cases per 100 000 persons.7,8 There are no ran-
domized clinical treatment trials determining the efficacy of
treatment, and management is stage dependent.
Historically, anumberof staging systemswereused forpa-
tients with MCC.9,10 These have since been consolidated into
the 2010 TNM staging system supported by both the Ameri-
can Joint Committee on Cancer (AJCC) and the International
Union for Cancer Control (Table 1).11,12 In addition, in recog-
nitionof the fairlyuniquestructureof theeyelid, theAJCCTNM
staging for eyelid carcinoma, 7th edition, was established to
provide a standardized approach to staging disease in this re-
gion (Table 2). However, to the best of our knowledge, there
are no studies ofMCCof the eyelid that have used either stag-
ing system. Given the few published series available to help
guide us in themanagement ofMCC of the eyelid, we present
ourexperiencewith21casesofprimaryMCCof theeyelidusing
both the eyelid and MCC AJCC TNM staging systems.
Methods
We conducted a multicenter, noncomparative case review of
all patientswithMCCpresenting to 5oculoplastic unitswithin
theUnitedKingdomandAustralia. Consecutivepatients from
Manchester Royal Eye Hospital, Royal Adelaide Hospital,
Moorfields EyeHospital in London,Royal SurreyCountyHos-
pital, andRoyalBrisbaneHospitalwhopresentedbetween1991
and 2012 with a histological diagnosis of MCC were included
in our study. Of the 21 cases in this series, only 1 was reported
previously.13
Clinical case notes were reviewed to obtain data, includ-
ing patient demographics, duration of signs and symptoms,
clinical presentation and staging, site of the tumor, imaging
findings, histopathological appearances, treatment modali-
ties, complications, and outcome. Each case was staged ac-
cording to initial clinical presentation using AJCC TNM stag-
ing for both eyelid carcinoma and MCC, 7th edition.
Institutional reviewboard/ethics committee approvalwasob-
tained for our study from all centers. All patient data were
de-identified.
Results
There were 21 cases of MCC identified over the 21-year pe-
riod.Of thesecases, 7were fromtheManchesterRoyalEyeHos-
pital, 5 were from the Royal Adelaide Hospital, 5 were from
Moorfields EyeHospital, 3were from theRoyal SurreyCounty
Hospital, and 1was fromtheRoyal BrisbaneHospital. Theme-
dian age at presentationwas 77 years (range, 58-91 years), and
52% (11 of 21 patients) were women. All patients were of Eu-
ropeandescent,with theexceptionofonewhowasofEastAfri-
canandAsiandescent.Themediandurationof symptomsprior
to presentation was 12 weeks (range, 4-39 weeks). The me-
dian follow-up period was 54 months (range, 4-252 months).
There were 2 patients who had associated hematological
disease. One had a history of chronic lymphocytic leukemia,
and the other received a diagnosis of multiple myeloma 10
months following the diagnosis of MCC.
Theupper lidwas involved in 17 cases (81%). Imagingwas
used for 10 patients (48%) to evaluate the extent of disease.
Four patients underwent magnetic resonance imaging of the
neck,4patientsunderwentcomputedtomographyof theneck,
and2patientsunderwent chest radiography.A sentinel lymph
node (SLN) biopsy was performed in 1 patient, whereas 2 pa-
tients presenting with clinical lymphadenopathy underwent
a nodal biopsy. The TNM stages for our patients at presenta-
tionaresummarized inTable3.Regionalnodalmetastaseswere
present in 2 patients at presentation who had clinical lymph-
adenopathy,whereas the remaining 18patients (86%)haddis-
ease localized to the eyelid.
Table 1. Definitions of TNM forMerkel Cell Carcinoma, AJCC Cancer
StagingManual, 7th Edition
Type Definition
Primary tumor (T)
TX Primary tumor cannot be assessed.
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor ≤2 cm in greatest dimension
T2 Tumor >2 cm, but not >5 cm, in greatest
dimension
T3 Tumor >5 cm in greatest dimension
T4 Primary tumor invades bone, muscle, fascia,
or cartilage.
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed.
cN0a No regional lymph node metastasis, based on
clinical evaluation or imaging
pN0b No regional lymph node metastasis, based on
lymph node biopsy
N1 Metastasis in regional lymph node
N1a Micrometastases
N1b Macrometastases
N2 In-transit metastasesc
Distant metastasis (M)
M0 No distant metastasis
M1 Metastasis beyond regional lymph nodes
M1a Metastasis to skin, subcutaneous tissue or
distant lymph nodes
M1b Metastasis to lung
M1c Metastasis to all other visceral sites
Abbreviation: AJCC, American Joint Committee on Cancer.
a Clinical N0.
bPathological N0.
c A tumor distinct from the primary lesion and located either between the
primary lesion and the draining regional lymph nodes or distal to the primary
lesion.
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Table 4 summarizes the management of MCC for our pa-
tients. Eighteen patients (86%) underwent a wide local exci-
sion (5-mmmargins) with margin control. Of these, 12 speci-
mens were processed with “fast paraffin” techniques, and 6
with frozen section. Two patients underwent a Mohs exci-
sion.Onepatient had aprimary exenteration after invasionof
the medial rectus detected by magnetic resonance imaging.
Two patients initially treated with a wide local excision re-
quired exenteration owing to an incomplete primary exci-
sion with orbital involvement.
Twelvepatients (57%) received adjuvant radiotherapy for
the eyelids, regional nodes, and intervening tissue following
awide local excision.Dosages ranged from55 to 59.4Gy. Both
patientswith regional nodal diseasewere treatedwithadjunc-
tive radiotherapy regardless of the size of theirMCCs.Onepa-
tientwhowas treated initiallywithanorbital exenterationalso
underwent radiotherapy.For the remaining9patientswithdis-
ease localized to the eyelid, the use of adjuvant radiotherapy
was center specific (Table 4). One patient underwent an evis-
ceration for a painful blind eye following radiotherapy. Of the
remaining 9 patients who did not receive adjuvant treat-
ment, 1developedsystemicmetastases6months following ini-
tial treatment (Table 5).
Two patients were recommended to undergo a func-
tional neck dissection. One patient with a 15-mm T2bN0M0/
T1N0M0 tumor underwent this procedure with a superficial
parotidectomy after being found to have regional nodal me-
tastases to thepreauricular andparotidnodes 1weekafter sur-
gery. However, the second patient who had presented with a
15-mm T2bN1M0/T1N1M0 tumor involving the submandibu-
lar nodes refused this treatment. This patient was 1 of 2 who
were treated with adjuvant chemotherapy. The second pa-
tient receivingchemotherapypresented initiallywithan8-mm
T2aN0M0/T1N0M0 tumor and developed thoracic metasta-
sis at 6 months follow-up. There were no reported adverse
events associated with chemotherapy.14
Nine patients (43%) had tumors greater than 2 cm in size,
classifying as stage II disease for both eyelid carcinoma and
MCCTNMstaging.Of these 9patients, 6were treatedwith ad-
junctive radiotherapy,whereas3 requiredanexenteration.One
patientwas recommended toundergoorbital exenterationbut
refused this treatment. There were 3 patients with tumors
greater than 2 cm in size who developed locoregional or dis-
tantmetastatic recurrences (Table 4), whereas the remaining
6 patients were free from recurrences at a median follow-up
of 75 months. Of the remaining 12 patients (57%) with a tu-
mor size of less than 2 cm, 1 with a 15-mm tumor presented
with regional nodal involvement, whereas another with a
15-mmtumorwas found tohave regional nodal disease 1week
after surgery. Six patients were treated with adjunctive local
radiotherapy. One patient with an 8-mm primary tumor who
didnot receiveradiotherapydevelopedbothregionalnodaland
distant metastatic recurrent disease 6 months after surgery.
None of the remaining patients with a primary tumor size of
less than 2 cmexperienced recurrence of theirMCCat last fol-
low-up (median, 36 months).
Table 5 describes features of recurrent MCC in our pa-
tients. Locoregional recurrencesoccurred in4patients and in-
cluded 2 local recurrences (10%) and 2 regional nodal recur-
rences (10%). All initial recurrenceswerewithin an 18-month
Table 2. Definitions of TNM for Eyelid Carcinoma, AJCC Cancer Staging
Manual, 7th Edition
Type Definitions
Primary tumor (T)
TX Primary tumor cannot be assessed.
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor ≤5 mm in greatest dimension; not invading
tarsal plate or eyelid margin
T2a Tumor >5 mm, but not >10 mm, in greatest
dimension, or any tumor that invades the tarsal
plate or eyelid margin
T2b Tumor >10 mm, but not >20 mm, in greatest
dimension; or, involves full thickness eyelid
T3a Tumor >20 mm in greatest dimension, or any
tumor that invades adjacent ocular or orbital
structures; any T with perineural invasion
T3b Complete tumor resection requires enucleation,
exenteration, or bone resection.
T4 Tumor is not resectable because of extensive
invasion of ocular, orbital, or craniofacial
structures or brain.
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
cN0a No regional lymph nodemetastasis, based on clini-
cal evaluation or imaging
pN0b No regional lymph nodemetastasis, based on lymph
node biopsy
N1 Regional lymph nodemetastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Abbreviation: AJCC, American Joint Committee on Cancer.
a Clinical N0.
bPathological N0.
Table 3. TNM Stages for 21 PatientsWithMCC of the Eyelid
Eyelid Carcinoma TNM
Stage (Prognostic Stage) Patients, No. (%) MCC TNM Stage (Prognostic Stage) Patients, No. (%)
T2aN0M0 (IB) 5 (24) T1N0M0 (IB) 12 (57)
T2bN0M0 (IC) 7 (33) T2N0M0 (IIB) 7 (33)
T3aN0M0 (II) 4 (19) T1N1M0 (IIIB) 1 (5)
T3bN0M0 (IIIA) 3 (14) T2N1M0 (IIIB) 1 (5)
T2bN1M0 (IIIB) 1 (5)
T3aN1M0 (IIIB) 1 (5) Abbreviation: MCC, Merkel cell
carcinoma.
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period. Neither patient with regional nodal recurrences was
investigatedatpresentationwithaSLNbiopsyorneck imaging.
There were 4 patients (19%) who developed systemic meta-
static recurrences.
Twopatients (10%)withstageT3a (eyelidTNM)/T2 (Merkel
TNM)tumorsdiedofmetastaticMCC,and6patients (29%)died
during follow-up of other causes. The remaining 13 patients
(62%) are alive and without evidence of disease at last me-
dian follow-up of 54 months.
Discussion
Our multicenter study represents, to the best of our knowl-
edge, the largest case series of primary MCCs of the eyelid to
date, with a median follow-up period of 54 months. Our se-
ries is also the first to use the AJCC TNM, 7th edition, staging
system for eyelid carcinoma andMCC. Although the primary
treatment for all our caseswas awide local excisionwithmar-
Table 5. Local, Regional, and DistantMetastatic Recurrent Cases ofMCC
Case No./Sex/Age, y
Tumor
Size, mm
Eyelid TNM Stage/
Merkel TNM Stage
Initial
Management
Time to Recurrence, mo
Treatment of
Recurrence
Cause of Death
(Follow-up)Local Regional Distant
1/F/69 8 T2aN0M0/T1N0M0 WLE 6 (parotid) 6 (chest) Parotidectomy,
chemotherapy
Unrelated to
MCC (75 mo)
2/M/77 25 T3bN0M0/T2N0M0 Exenteration,
RXT
5 (chest,
bone marrow)
RXT Unrelated to
MCC (5 mo)
3/F/75 37 T3aN0M0/T2N0M0 WLE, RXT 18 12 (parotid) 18 (systemic) RXT Metastatic MCC
(90 mo)
4/M/85 22 T3aN1M0/T2N1M0 WLE, RXT 8 8 (systemic) RXT Metastatic MCC
(8 mo)
Abbreviations: CLL, chronic lymphocytic leukemia; MCC, Merkel cell carcinoma; RXT, radiotherapy; WLE, wide local excision.
Table 4. Management of PatientsWithMerkel Cell Carcinoma of the Eyelid
Institution,
Patient No. Imaging
Eyelid TNM/
Merkel TNM Stage
Prognostic Stage
(Eyelid TNM/
Merkel TNM) Treatment
Adjuvant
Treatment
Royal Brisbane
Hospital Herston
1 T3bN0M0/T2N0M0 IIIA/IIB WLE (5 mm),
exenteration
Manchester Royal
Eye Hospital
2 T2aN0M0/T1N0M0 IB/IB WLE (5 mm)
3 T2bN0M0/T1N0M0 IC/IB WLE (5 mm)
4 MRI T3bN0M0/T2N0M0 IIIA/IIB Exenteration RXT
5 T3aN0M0/T2N0M0 II/IIB WLE (5 mm)
6 T2bN0M0/T1N0M0 IC/IB WLE (5 mm)
7 T2bN0M0/T1N0M0 IC/IB WLE (5 mm) RXT
8 T3aN0M0/T2N0M0 II/IIB WLE (5 mm)
Moorfields
Eye Hospital
9 CT T2aN0M0/T1N0M0 IB/IB WLE (5 mm)
10 CXR T3aN0M0/T2N0M0 II/IIB WLE (5 mm) RXT
11 T2bN0M0/T1N0M0 IC/IB WLE (5 mm) RXT
12 CXR T3bN0M0/T2N0M0 IIIA/IIB WLE (5 mm),
exenteration
13 T2N0M0/T1N0M0 IC/IB Mohs surgery
Royal Adelaide
Hospital
14 MRI T2aN0M0/T1N0M0 IB/IB WLE (5 mm) RXT
15 MRI, SNB T2aN0M0/T1N0M0 IB/IB WLE (5 mm) RXT
16 SNB T2bN1M0/T1N1bM0 IIIB/IIIB Mohs surgery RXT
17 MRI T2aN0M0/T1N0M0 IB/IB WLE (5 mm) RXT
15 T2bN0M0/T1N0M0 IC/IB WLE (5 mm) RXT
Royal Surrey
County Hospital
19 CT T2bN0M0/T1N0M0 IC/IB WLE (5 mm) RXT
20 CT T3aN1M0/T2N1bM0 IIIB/IIIB WLE (5 mm) RXT
21 CT T3aN0M0/T2N0M0 II/IIB WLE (5 mm) RXT
Abbreviations: CT, computed
tomography; MRI, magnetic
resonance imaging;
RXT, radiotherapy; SNB, sentinel
node biopsy; WLE, wide local
excision.
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gin control, theuseofprophylactic radiotherapy toprevent re-
current disease was institution specific. The smallest tumor
associatedwithboth regionalnodal anddistantmetastaticdis-
easewas of T categoryT2a (eyelidTNM)/T1 (Merkel TNM).We
demonstrated lower rates of locoregional and distant meta-
static recurrence compared with MCCs in other body loca-
tions. In addition, we found a disease-specific mortality rate
of 10%,which is also significantly lower than the reported rates
for MCCs in general.
Data specific toMCCof the eyelid is scarce, and, to date, a
total of 97 cases of primary MCC of the eyelid have been re-
ported in the literature (Table 6). Among these 97 cases, there
was a local recurrence rate of 14%, a regional nodal recur-
rence rate of 20%, and a distant metastatic recurrence rate of
5%. Only 2 patients (2%) with primary MCC of the eyelid had
regional nodal or distantmetastatic involvement at presenta-
tion, and the disease-specific mortality rate was 6%. In our
study,we report lower rates of local and regional nodal recur-
Table 6. Literature Review of PrimaryMerkel Cell Carcinoma of the Eyelid
Source, y
Primary
Cases
(N = 97)
Initial Treatment
(No. of Cases)
Median
Follow-up, mo
No. of Cases (Time to Event, mo)a
Mortality,
No. of Patients
Local
Recurrence
Regional Nodal
Involvement
Distant
Metastases
Kivelä and
Tarkkanen,14
1990b
35 Excision (10); excision,
RXT (2); WLE (5); WLE,
RXT (2); RXT (1)
6.5 4 8 (3, 3, 3, 3, 8) 2 2
Bayrou et al,15
1990
2 Excision (2) 17 0 0 0 0
Rubsamen et al,16
1992
4 WLE, FS (2); WLE (2);
WLE, RXT (1)
24 0 1 (4) 1 (>12) 1
Furuno et al,17
1992
1 WLE, cryopexy (1) 48 1 (6) 1 (6) 0 0
Hamilton et al,18
1993
2 WLE (1); WLE, FS (1) 67 0 0 0 0
Coskuncan et al,19
1994
1 WLE, FS, RXT (1) 9 0 1 (7) 0 0
Soltau et al,20
1996
2 WLE (1); WLE, FS (1) Unknown 0 0 0
Dini and Russo,21
1997
1 RXT (1) 2 0 0
Metz et al,22 1998 6 Unknown Unknown 1 Unknown Unknown Unknown
Ott et al,23 1999 1 RXT (1) 60 0 0 0 0
Di Maria et al,24
2000
2 Excision (2) 46 2 (9, 48) 1 (12) 0 0
Colombo et al,25
2000
4 WLE, FS (3); WLE (1) 48 0 0 0 0
Giacomin et al,26
2000
3 WLE (3) 67 0 1 (12) 0 0
Peters et al,27
2001
14 WLE (11); Mohs surgery
(1); WLE, RXT (1); WLE,
RXT, chemotherapy (1)
24 0 3 (11, 12, 30) 0 1
Sinclair et al,28
2003
1 RXT (1) Unknown
Nicoletti et al,29
2004
3 WLE (2); WLE, FS (1) 12 0 0 0 0
Onesti et al,30
2005
2 Excision (3) 10 3 (2, 3, 6) 1 (2) 0 0
Pathai et a,31 2005 1 Excision (1) 35 1 (4) 0 0 0
Rawlings et al,32
2007
1 Excision (1) 13 1 (7) 0 1 (13) 1
Marshmann and
McNab,33 2007
2 WLE (2) 6 1 (4) 0 0 0
Missotten et al,34
2008
3 WLE, FS, RXT(1); WLE, FS
(1); WLE (1)
24 0 0 0 0
Saedon and
Hubbard,35 2008
1 WLE, FS, and
chemotherapy
8 0 0 0 0
Tanahashi et al,36
2009
1 Excision, lymphadenec-
tomy (1)
72 0 1 (0) 0 0
Kase et al,37 2010 1 Excision (1) Unknown 0 1 (7) 1 (12) 0
Bleyen et al,38
2010
2 Excision, FS, RXT (1);
Mohs surgery, RXT (1)
39 0 1 (4) 0 0
Chen et al,39 2011 1 1 (0) 1 (0) 1
Abbreviations: FS, frozen section; RXT, radiotherapy; WLE, wide local excision.
a If known.
b Systematic review of 34 previously reported cases and 1 additional case.
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rence, 10% for both, but found a higher rate of metastatic re-
currence at 19%. In addition,wehad 2patients (10%) present-
ing initiallywith clinically evident regional nodal disease and
ahigherdisease-specificmortality rateof 10%.However, these
figures remain lower than that reported for MCCs in general,
suggesting thatMCCsof theeyelidcarryabetterprognosis.This
may be related to earlier detection of eyelid lesions, with 52%
of our patients presentingwith primary lesions less than 2 cm
in size (stage I).
Primary treatmentofMCC inour series consistedof awide
excision with margin control or Mohs micrographic surgery
with or without adjunctive radiotherapy. A wide local exci-
sion with 2.5- to 3-cmmargins is generally recommended for
cutaneous MCC.23,40,41 However, Peters et al27 demonstrated
effective local controlwith 5-mmmargins forMCCof the eye-
lid, in keepingwithmanagement guidelines for other aggres-
sive malignant eyelid lesions. Although a Mohs excision has
beenused to treatMCCs affectingother cutaneous sites, there
are only 3 reports27,31,38 of Mohs surgery for MCC of the eye-
lid, and one of these involved a recurrent MCC in which the
initial surgicalmanagementwas excision. The size of the sur-
gicalmargin has not been shown to correlatewith the locore-
gional recurrence rate because recurrences have been re-
ported even after a wide excision with negativemargins.42,43
In our series, 3 of 4 patients who developed recurrences un-
derwent awide local excisionwithmargin control as their ini-
tial surgical management.
The role of radiotherapy in the management of MCC re-
mainscontroversial.Althoughanumberof studieshaveshown
improvement in locoregional control,23,43,44 the evidence for
improvement in disease-specific mortality is inconclusive.43
Over half of our patients (57%) received adjuvant radio-
therapy following surgery.However, of the4patientswhode-
veloped locoregional or distantmetastatic recurrences, 3 had
received radiotherapy. In addition, both patients who died of
metastaticMCChad received adjuvant radiotherapy after sur-
gery. Although there may be a role for the use of adjuvant ra-
diotherapy to prevent recurrence in localized disease, fur-
ther studies are required todeterminepatient selection for this
treatment modality.
The AJCC staging system for MCCwas first introduced in
2010 to standardize staging and improve comparability with
staging systems for other skin cancers.11 In addition, theAJCC
updated their staging for eyelid carcinoma in the 7th edition
to improve its practical application.45 Because the AJCC eye-
lidTNMstages allow for finerdiscriminationof tumor size and
extent to reflect the unique structure of the eyelid, this may
be preferred over the Merkel TNM staging system. However,
additional studies using the 2 staging systems are required to
further investigate their practical application. Stage II dis-
ease for theAJCCTNMeyelid carcinomaandMCCstaging sys-
tem refers to localized disease where primary tumor size ex-
ceeds 2 cm. Previously established poor prognostic factors
include tumors greater than 2 cm in size, being older than 65
yearsof age, beingamalepatient, locoregional recurrence, and
distant metastases.27,44,46 In keeping with previous reports,
both MCC-related deaths within our series occurred in pa-
tients with a primary tumor greater than 2 cm in size and dis-
tant metastatic disease. Of these 2 patients, 1 was a man pre-
sentingwith stage III disease,whereas theotherwas awoman
presentingwithstage IIdisease.Wealsohad1patientwitheye-
lid T category T2a andMerkel T category T1measuring 8mm
whosubsequentlydeveloped regionalnodal anddistantmeta-
static recurrences. This patient died of an unrelated disease,
but this highlights the importance of careful surveillance for
MCC regardless of stage and size.
A pathologic nodal evaluation has been shown to im-
prove prognostic accuracy, and previous studies have sug-
gested that SLN mapping and excision may be a useful ad-
junct in the treatmentofMCC.12,47However, there is conflicting
evidence regarding the association of SLN status anddisease-
specific survival.42,48Despite this, anSLNbiopsyhasbeen rec-
ommended for all MCCs of the eyelid and conjunctiva, al-
though further prospective studies have been advocated.49
Only1patient inourseriesunderwentanSLNbiopsy,withhead
andneck imagingbeing themorecommonformof regionaldis-
ease assessment. None of the 4 patients who developed lo-
coregional nodal and/or distant metastatic recurrences were
investigated initially with an SLN biopsy. Furthermore, the
smallest tumor inour series associatedwith regionalnodal and
distant metastatic disease was an 8-mmT2a (eyelid TNM)/T1
(Merkel TNM) tumor. This is in keeping with 3 previous re-
portsofMCCof theeyelid in the literature,27,31,38 inwhichsmall
tumors (≤10mm) localized to the eyelid have been associated
with regionalnodal recurrences.14,27 This suggests that anodal
evaluationviaanSLNbiopsyor imagingfollowedbystrictnodal
surveillance may be appropriate for all patients with MCC of
the eyelid. There has also been increasing evidence to sup-
port the use of positron emission tomography in the staging
ofMCC,withoneretrospectivestudy50demonstratingachange
in staging for 33% of their patients, and a change in manage-
ment for 43% of their patients following a positron emission
tomographic scan. Although the most appropriate follow-up
method and frequency for patients with MCC have not been
studiedprospectively,most studies recommended regular ex-
aminationsof the localdisease siteand the regionalnode, clini-
callyandwith imaging if indicated.14,51 It shouldbenoted,how-
ever, that there is no evidence to suggest that early detection
of regional recurrence improves survival. For high-risk cases
(higherT categoryornodal involvement), consideration could
be given to regular (2- to 6-month) nodal surveillancewithul-
trasonography forat least the first 3years.Reportsofnodal sur-
veillancewithultrasonography forheadandneck short course
chemotherapy suggest that this modality, in the hands of an
experiencedoperator,hasgoodsensitivityandspecificitycom-
pared with computed tomography/magnetic resonance
imaging.52
Two patients in our series presented with regional nodal
disease, and a functional neck dissection was recommended
for both; however, 1 patient refused this treatment andwas in-
stead treated with chemoradiotherapy. This patient was 1 of
the 2 patients who received chemotherapy, a treatment that
is generally reserved for distant metastatic disease for pallia-
tion rather than cure.23,27 Voog et al53 found a 60% response
rate to chemotherapy in patients withMCC, inwhich theme-
dianoverall survival after startingchemotherapywas9months
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for patientswithdistantmetastatic disease and 24months for
patientswith locoregional disease. Inour series, 1 patientwith
regional nodal and distant metastatic recurrences was suc-
cessfully treated with chemotherapy and died of unrelated
causes 75 months after treatment. The second patient is also
without recurrent disease at 12 months, although continued
follow-up and additional studies are required to better define
the role of chemotherapy for MCC.
In a recent reviewof the literature,Missotten et al34 iden-
tified3previous reportsofpatientswithchronic lymphatic leu-
kemia (CLL) and MCC of the eyelid. Our study adds an addi-
tional patient to this group. This patient had established CLL
and was receiving immunosuppressive therapy prior to de-
velopingMCC.Hepresentedwith tumor invasion into theme-
dial rectus, which required an orbital exenteration, and sub-
sequently developedmetastaticMCC but died 5months after
diagnosis of complications of CLL. Recent studies have dem-
onstrated that patients with CLL have a high risk of develop-
ing MCCs containing Merkel cell polyomavirus owing to im-
munosuppression related to CLL and viral infection.54 In
addition, patients with CLL who subsequently develop MCC
havebeenshowntohavesignificantlyworseoverall andcause-
specific survival compared with patients without CLL.55 Our
patient with CLL developed systemic metastases within the
shortest time from initial diagnosis, compared with all other
patients with systemic metastatic recurrences, and survived
the shortest time after development of metastases.
Our study has a number of limitations that warrant men-
tioning. Our multicenter, retrospective study design in-
cluded centers with differing treatment protocols, particu-
larlywith respect to the use of prophylactic radiotherapy and
nodal assessment, thusmaking the correlationbetweenTcat-
egory in the TNMstaging system and outcomedifficult. This,
however, reflects the lack of standardized treatment ap-
proaches toMCCof the eyelid, owing to its rarity, and encour-
ages future research touse standard reportingwithTNMstag-
ing. This would enable us to better estimate the prognosis for
individual patients andwould also enhance our ability to de-
terminewhichpatientsmaybenefit from lymphnode surveil-
lanceoranSLNbiopsy. Inaddition,previous reportshavedocu-
mented that 90%of recurrences tend to occurwithin the first
2 years after primary diagnosis,10,42 and although ourmedian
follow-upperiodwas 54months, further recurrencesmayoc-
cur beyond this period.Additional follow-up is required to as-
sess the recurrence rate in our patients in order to assess the
efficacy of treatment.
Conclusions
Merkel cell carcinoma of the eyelid is associated with sig-
nificant rates of recurrence and metastases, as well as a sig-
nificant mortality rate. Compared with MCCs occurring in
other locations, MCCs of the eyelid appear to be associated
with a better prognosis, which may be related to earlier
detection. A wide local excision with 5-mm margins and
histological margin control remains the mainstay of treat-
ment, and adjuvant radiotherapy may play a role in preven-
tion of recurrent disease for selected patients. However,
recurrent disease and regional/distant metastases do occur
in patients who have disease localized to the eyelid or a
lower T category tumor and in those who receive prophylac-
tic radiotherapy. Hence, an SLN biopsy or a radiological
nodal assessment should be considered for all patients with
MCC of the eyelid as part of the initial staging process, and
strict nodal surveillance may be useful in detecting early
recurrent disease. TNM staging should be used to plan the
management of patients and also should be adopted in
future studies to better enhance comparison between stud-
ies. Because the TNM staging for eyelid carcinoma enables a
finer discrimination of tumor size and extent, we would
favor its use over the Merkel staging system.
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